[CAS NO. 136087-85-9] Fidarestat
PRODUCTS SPECIFICATIONS [136087-85-9]
DESCRIPTION [136087-85-9]
Overview
| MDL | MFCD00919183 |
|---|---|
| Molecular Weight | 279.22 |
| Molecular Formula | C12H10FN3O4 |
| SMILES | O=C1NC(N[C@@]12C3=C(C=CC(F)=C3)O[C@H](C(N)=O)C2)=O |
1 Publications Citing Use of MCE
Summary
Fidarestat (SNK 860) is an inhibitor of aldose reductase , with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase , AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
IC50 & Target
IC50: 26 nM (Aldose reductase), 33 μM (AKR1B10), 1.8 μM (V301L AKR1B10) [1]
In Vitro
Fidarestat is an inhibitor of aldose reductase, with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Fidarestat (SNK-860; 1 or 4 mg/kg. p.o., daily for 4 weeks) reduces the concentrations of sorbitol and fructose in diabetic rats [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 895.35 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5814 mL | 17.9070 mL | 35.8141 mL |
| 5 mM | 0.7163 mL | 3.5814 mL | 7.1628 mL |
| 10 mM | 0.3581 mL | 1.7907 mL | 3.5814 mL |
References
- [1] Ruiz FX, et al. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. Chem Biol Interact. 2013 Feb 25;202(1-3):178-85.
- [2] Hotta N, et al. Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. Exp Physiol. 1995 Nov;80(6):981-9.
Synonyms
